Improved survival of stage 4 high grade ovarian cancer patients as staged by positron emission tomography (PETCT), who undergo chemotherapy (with a good PETCT response) and debulking surgery as seen in a prospective study in our cancer institution....
Ovarian cancer (OC) is the fifth most common malignant female cancer with a high mortality, mainly because of aggressive high-grade serous carcinomas (HGSOC), but also due to absence of specific early symptoms and effective detection strategies. The CXCL12-CXCR4 axis is considered to have a ...
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, ... Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and tol...
and a right ovarian cancer but also had a STIC in the left FT (Supplementary Fig.5). In this case the SCHISM analysis suggested that the lesion in the left FT which was pathologically determined to be a STIC actually represented a metastatic lesion of the right ovarian cancer (Fig.4). T...
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive type of ovarian cancer, often diagnosed at advanced stages. Molecularly, HGSOC shows high degree of genomic instability associated with large number of genetic alterations. BRD4 is the 4t
Purpose: Here we assess whether molecular subtyping identifies biological features of tumors that correlate with survival and surgical outcomes of high-grade serous ovarian cancer (HGSOC).Experimental Design: Consensus clustering of pooled mRNA expression data from over 2,000 HGSOC cases was used to...
In contrast, low-grade serous ovarian cancers (LGSOCs) appear to have different pathological, epidemiological, and clinical features and should be seen as a distinct serous epithelial ovarian cancer subtype. Our current understanding of LGSOC is limited, and treatment has generally been derived from...
No consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This study aimed to explore the optimal timing for ID
Moreover, MSLN’s impact on the ovarian cancer microenvironment was known to be involved in cell survival, proliferation, tumor progression, and adherence41. MSLN has been shown to bind to CA-125 and is thought to play a role in the peritoneal diffusion of ovarian tumor cells41. A recent...
As illustrated in Table 1, none of the three tumor groups, including those with classic features of high-grade endometrioid carcinoma, could be dis- tinguished on the basis of the expression of three biomarkers that have been recently studied in ovarian cancer. p53, WT-1 and p16ink4, which...